drugset / Trial / NCT00453193
Alemtuzumab and Pentostatin In T-cell Neoplasms
Phase 2
Terminated
26 enrolled
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc. · collabBayer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab can help to control T-cell malignancy. The safety of this combination therapy will also be studied.
Timeline
- Start
- 2004-09
- Primary completion
- 2010-03
- Completion
- 2010-03
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Pentostatin | Small molecule | 4 mg/m2 | Intravenous |